Evidence map›Paper›PMID 26571151›Full record

ArticleAIDS research and human retroviruses2016

HIV-1 CRF01_AE and Subtype B Transmission Networks Crossover: A New AE/B Recombinant Identified in Japan.

Masumi Hosaka, Seiichiro Fujisaki, Aki Masakane, Junko Hattori, Teiichiro Shiino, Hiroyuki Gatanaga, Urara Shigemi, Reiko Okazaki, Atsuko Hachiya, Masakazu Matsuda and 5 more

Open access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Masumi Hosaka1 Clinical Research Center, National Hospital Organization Nagoya Medical Center , Nagoya, Japan .
Seiichiro Fujisaki1 Clinical Research Center, National Hospital Organization Nagoya Medical Center , Nagoya, Japan .
Aki Masakane2 Department of Clinical Laboratory, Yamaguchi University Hospital , Yamaguchi, Japan .
Junko Hattori1 Clinical Research Center, National Hospital Organization Nagoya Medical Center , Nagoya, Japan .
Teiichiro Shiino3 Infectious Disease Surveillance Center, National Institute of Infectious Diseases , Tokyo, Japan .
Hiroyuki Gatanaga4 AIDS Clinical Center, National Center for Global Health and Medicine , Tokyo, Japan .
Urara Shigemi1 Clinical Research Center, National Hospital Organization Nagoya Medical Center , Nagoya, Japan .
Reiko Okazaki1 Clinical Research Center, National Hospital Organization Nagoya Medical Center , Nagoya, Japan .
Atsuko Hachiya1 Clinical Research Center, National Hospital Organization Nagoya Medical Center , Nagoya, Japan .
Masakazu Matsuda1 Clinical Research Center, National Hospital Organization Nagoya Medical Center , Nagoya, Japan .
Shiro Ibe1 Clinical Research Center, National Hospital Organization Nagoya Medical Center , Nagoya, Japan .
Yasumasa Iwatani1 Clinical Research Center, National Hospital Organization Nagoya Medical Center , Nagoya, Japan .
Yoshiyuki Yokomaku1 Clinical Research Center, National Hospital Organization Nagoya Medical Center , Nagoya, Japan .
Wataru Sugiura1 Clinical Research Center, National Hospital Organization Nagoya Medical Center , Nagoya, Japan .
Japanese Drug Resistance HIV-1 Surveillance Network Team
Nagoya Medical Center · JPNational Hospital Organization · JPNagoya University · JPNational Center for Global Health and Medicine · JPNational Institute of Infectious Diseases · JPYamaguchi University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The major circulating HIV-1 strains in Japan have been subtype B (B) followed by CRF01_AE (AE) in newly diagnosed HIV/AIDS cases. These two subtypes have distinct epidemiological characteristics; B predominates in men who have sex with men, while AE is observed mostly in heterosexuals engaging in high-risk sex. However, transmission networks of these two high-risk populations appear to be crossing over and diffusing. Here we report the emergence of previously unidentified HIV-1 AE/B recombinants in Japan. We initially identified 13 cases with discordant subtyping results with AE (gag MA)/B (pol PR-RT)/AE (env C2V3) by molecular phylogenetic analysis of 1,070 cases who visited Nagoya Medical Center from 1997 to 2012. Genetic characterization of full-length sequences demonstrated that they shared an identical recombinant structure, and was designated as CRF69_01B by the Los Alamos HIV National Laboratory. By reviewing gag, pol, and env sequences collected in the Japanese Drug Resistance HIV-1 Surveillance Network, we found five other CRF69_01B probable cases from different areas in Japan, suggesting that the strain is transmitted widely throughout the country. The time of the most recent common ancestor analyses estimated that CRF69_01B emerged between 1991 and 1995, soon after AE was introduced from neighboring countries in the mid-1990s. Understanding the current epidemic strains is important for the diagnosis and treatment of HIV/AIDS, as well as for the development of globally effective HIV vaccines.

Indexed as

Base Sequenceenv Gene Products, Human Immunodeficiency Virusgag Gene Products, Human Immunodeficiency VirusGenotypeHIV-1HIV InfectionsHomosexuality, MaleHumansJapanMaleMolecular EpidemiologyPhylogenypol Gene Products, Human Immunodeficiency VirusRecombination, GeneticSequence Analysis, DNAUnsafe Sexenv Gene Products, Human Immunodeficiency Virusgag Gene Products, Human Immunodeficiency Viruspol Gene Products, Human Immunodeficiency Virus

Identifiers

PMID26571151
PMCPMC4845645
OpenAlexW1730183509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.